---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-23-000072"
form_type: "8-K/A"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T13:41:33.278965+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health Q2 revenue $2.5M, up 23% YoY; cash burn down 46%

## Summary
- Q2 2023 revenue $2.5M (+23% YoY); OvaSuite volume 6,289 (+16%); gross margin 62% vs 47% in Q2 2022.
- Cash used in operations $3.4M, down 46% from $6.3M in Q2 2022; total cash $4.5M at June 30.
- Lowered H2 2023 operating cash guidance to $6–8M; received $1M debt forgiveness from Connecticut DECD.
- Raised $4.3M net in July 2023 registered direct offering; total outstanding debt ~$1.6M.
- Appointed Torsten Hombeck as CFO; COO/CSO Ryan Phan to depart Sept 15; new director Winfred Parnell appointed.

## SEC filing metadata
- accession: 0000926617-23-000072
- form_type: 8-K/A
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/0000926617-23-000072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/awh-20230814x8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-23-000072
- JSON: https://secwatch.observer/filing/0000926617-23-000072.json
- Plain text: https://secwatch.observer/filing/0000926617-23-000072.txt

## Key facts
- Earnings Releases
  Aspira Women's Health Inc. reported second quarter ended June 30, 2023 results: revenue $2.5 million. Guidance lowered.
  - Period: second quarter ended June 30, 2023
  - Revenue: $2.5 million
  - Guidance: lowered
  - Result: reported results
  source text: (EX-99.1) --- 2023-08-14 8K Ex 991 Exhibit 99 .1 Aspira Women’s Health ® Reports Second Quarter 2023 Financial Results  Continued growth trend with second quarter revenue of $2.5 million, an increase of 23% over the second quarter of 2022. OvaSuite volume of 6,289 units, an increase of 16% year-over-year Achieved cash used in operations of $3.4 million, a
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661723000072/0000926617-23-000072-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.